Skip to main content
. 2014 Nov 13;11:188. doi: 10.1186/s12974-014-0188-1

Table 4.

Cerebrospinal fluid (CSF) and serum levels (median and IQR) and intrathecal synthesis of anti-Epstein Barr nuclear antigen 1 (EBNA-1) and anti-viral capsid antigen (VCA) IgG in patients with relapsing-remitting multiple sclerosis (RRMS), other inflammatory neurological disorders (OIND) and noninflammatory neurological disorders (NIND)

Anti-EBNA-1 IgG Anti-VCA IgG
CSF levels (AU) Serum levels (AU) AI >1.5 CSF levels (AU) Serum levels (AU) AI >1.5
Median; IQR Median; IQR n/total (%) Median; IQR Median; IQR n/total (%)
Total RRMS (n = 100) 79.4; 37.5 to 174.3a 52,056; 23,274 to 94,815c, d 6/100 (6%) 36.4; 0.0 to 74.2 18962; 10659 to 46669 2/100 (2%)
CA RRMS (n = 77) 74.8; 38.2 to 167.7 41,783; 21,479 to 83,254 4/77 (5.2%) 41.9; 0.0 to 83.1 22546; 12433 to 51763 0/77 (0%)
CS RRMS (n = 23) 100.4; 51.0 to 272.7 59833; 36072 to 261044 2/23 (8.7%) 21.1; 0.0 to 59.9 14240; 6632 to 32515 2/23 (8.7%)
Gd + RRMS (n = 37) 90.4; 36.7 to 238.7 39325; 21479 to 105629 3/37 (8.1%) 23.7; 0.0 to 60.9 16836; 12476 to 37484 0/37 (0%)
Gd- RRMS (n = 63) 79.4; 43.3 to 139.0 53092; 27500 to 84551 3/63 (4.8%) 38.9; 0.0 to 85.1 21335; 10036 to 47672 2/63 (3.4%)
OIND (n = 100) 73.1; 31.0 to 151.6b 23503; 10386 to 44089 6/100 (6%) 82.7; 30.3 to 294.1e, f 29938; 8846 to 65475 5/100 (5%)
NIND (n = 100) 49.7; 15.9 to 118.9 24383; 7252 to 54754 2/100 (2%) 39.1; 0.0 to 130.8 28056; 12281 to 53124 1/100 (1%)

CSF anti-EBNA-1 IgG levels (Mann- Whitney with Bonferroni correction): aMS versus NIND (p <0.01); bOIND versus NIND (p <0.05). Serum anti-EBNA-1 IgG levels (Mann- Whitney with Bonferroni correction): cMS versus OIND (p <0.0001); dMS versus NIND (p <0.0001). CSF anti-VCA IgG levels (Mann- Whitney with Bonferroni correction): eOIND versus MS (p <0.0001); fOIND versus NIND (p <0.01). AI >1.5, antibody index abnormal values indicative of EBV-specific intrathecal synthesis; AU, arbitrary units; CA, clinically active (presence of relapse at entry); CS, clinically stable (absence of relapse at entry); Gd +, appearance of gadolium enhancing lesions on magnetic resonance imaging (MRI); Gd- , no evidence of gadolium enhancing on MRI; IQR, Interquartile Range; MS, multiple sclerosis; NIND, noninflammatory neurological diseases; OIND, other inflammatory neurological diseases.